ORIC Pharmaceuticals, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 9.24 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 957.75M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Details
| Name | ORIC Pharmaceuticals, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 111 |
| Founded | 2014 |
| Ipo Date | 2020-04-24 |
| Ceo | Jacob Chacko |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 16.00 |
| Isin | US68622P1093 |
| Cusip | 68622P109 |
| Cik | 1796280 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Jacob M. Chacko M.B.A., M.D. | President, Chief Executive Officer and Director |
| Dr. Richard A. Heyman Ph.D. | Founder, Independent Chairman and Member of Scientific Advisory Board |
| Dominic G. Piscitelli CPA, M.B.A. | Chief Financial Officer |
| Dr. Pratik S. Multani M.D., M.S. | Chief Medical Officer |
| Dr. Charles L. Sawyers B.A., M.D., Ph.D. | Founder and Member of Scientific Advisory Board |
| Dr. Scott W. Lowe Ph.D. | Founder and Member of Scientific Advisory Board |
| Dr. Kevin Brodbeck Ph.D. | Chief Technical Officer |
| Dr. Lori Sickels Friedman Ph.D. | Chief Scientific Officer |
| Daniel Iazzetti | Vice President and Head of People |
| Dr. Edna Chow Maneval Ph.D. | Executive Vice President of Clinical Development |
Contact
| Address | 240 E. Grand Ave, 2nd Floor, South San Francisco, California 94080, United States |
| Phone | 650 388 5600 |
| Website | https://www.oricpharma.com |